Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mitomycin C in glaucoma surgery]

J Collignon-Brach1

  • 1Centre Hospitalier Universitaire, Service d'Ophtalmologie, Université de Liège.

Bulletin De La Societe Belge D'Ophtalmologie
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Low dose intravitreal triamcinolone acetonide in the treatment of neovasular glaucoma].

Bulletin de la Societe belge d'ophtalmologie·2006
Same author

[Acute glaucoma crisis].

Revue medicale de Liege·2004
Same author

[Non perforating trabecular surgery with reticulated hyaluronic acid implant].

Bulletin de la Societe belge d'ophtalmologie·2000
Same author

[Interest in ophthalmologic examination for familial adenomatous polyposis].

Bulletin de la Societe belge d'ophtalmologie·2000
Same author

Ambulatory blood pressure monitoring in glaucoma patients. The nocturnal systolic dip and its relationship with disease progression.

International ophthalmology·1999
Same author

[Interest in the Heidelberg Retinal Flowmeter for measuring the retinal and papillary blood flow].

Bulletin de la Societe belge d'ophtalmologie·1999
Same journal

Didactic image poppers maculopathy.

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Marcus Gunn Syndrome. Study of 3 rare cases].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Ocular manifestations of children living with HIV/AIDS in Kinshasa].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Management of rhegmatogenous retinal detachment with unseen breaks: about 50 cases].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

Long term IOP lowering efficacy of bimatoprost/timolol fixed combination: a 12 month prospective study.

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Palpebral pilomatricoma simulating a chalazion in a young adult].

Bulletin de la Societe belge d'ophtalmologie·2014
See all related articles

Mitomycin C (MMC) is more effective than 5-fluorouracil (5-FU) in preventing scarring after glaucoma filtering surgery. MMC offers a better success rate and fewer complications, though further human studies are needed.

Area of Science:

  • Ophthalmology
  • Surgical Innovation
  • Wound Healing Research

Background:

  • Glaucoma filtering surgery success is limited by bleb scarring from fibroblast proliferation.
  • Antimetabolites can enhance surgical outcomes by inhibiting fibroblast proliferation.
  • Current treatments like 5-fluorouracil have drawbacks, including patient discomfort and ocular surface issues.

Purpose of the Study:

  • To compare the efficacy of Mitomycin C (MMC) versus 5-fluorouracil (5-FU) in preventing scarring after glaucoma filtering surgery.
  • To evaluate the impact of MMC on intraocular pressure and ocular surface complications.

Main Methods:

  • Review of existing clinical and tissue culture studies comparing MMC and 5-FU.
  • Analysis of success rates and complication profiles associated with each antimetabolite.

Related Experiment Videos

Main Results:

  • MMC demonstrated a significantly higher success rate (88%) at one year compared to 5-FU (40%).
  • MMC's antiproliferative effect is substantially more potent than 5-FU.
  • Intraoperative MMC application resulted in better hypotensive effects and fewer corneal complications.

Conclusions:

  • Mitomycin C appears to be a superior agent to 5-fluorouracil for enhancing glaucoma filtering surgery outcomes.
  • MMC may offer advantages due to its potency and localized application, reducing toxicity.
  • Long-term, randomized prospective human studies are required to definitively confirm MMC's long-term benefits.